|Day Low/High||11.87 / 12.19|
|52 Wk Low/High||6.96 / 25.00|
First Study Evaluating Combination of PEGPH20 and atezolizumab in Pancreatic Cancer
--Findings in Two Oral Presentations and Three Poster Presentations Continue to Support Ongoing HALO-301 Phase 3 Study--
The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 3,135,029 share decrease in total short interest for Halozyme Therapeutics Inc , to 21,693,822, a decrease of 12.63% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
-Presentation Includes Newly Reported Objective Response Rate and Patient Baseline Characteristics from HALO-202-
Lion Biotechnologies, XBiotech and Halozyme Therapeutics were among the biotech movers in premarket trading on Friday.
-HALO-202 Study Met Primary, Key Secondary Endpoints and Demonstrated a Statistically Significant Improvement in Progression-Free Survival (PFS) in Patients with High Levels of Hyaluronan-
Here's how to potentially rake in some fat profits off a number of hot breakout setups.
Halozyme Therapeutics, Omeros and Aralez Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.
The market response to the Fed was quite extreme, although there really wasn't any major development.
Jim Cramer interviews CEOs from Constellation and Halozyme about their businesses and their stocks' wild ride.
Jim Cramer says this rally relies on a speedy end to regulation, fast repatriation of foreign money and corporate tax reform.
Investors in Halozyme Therapeutics Inc saw new options begin trading this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HALO options chain for the new February 2017 contracts and identified one put and one call contract of particular interest.
In recent trading, shares of Halozyme Therapeutics Inc have crossed above the average analyst 12-month target price of $13.15, changing hands for $13.83/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
If investing is like a horserace, you can change horses in the middle of the race.
Energy and consumer defensive names dominate on the bearish side.